Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies Bethany BarehamNikitas GeorgakopoulosKourosh Saeb-Parsy Review Open access 08 April 2021 Pages: 2737 - 2750
Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy Mohamed Labib SalemSamar SalmanIbrahim O. Barnawi Review 08 May 2021 Pages: 2751 - 2759
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events Andrew NashedShijun ZhangLang Li Original Article 24 February 2021 Pages: 2761 - 2769
Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review Yuli Guzman-PradoJennifer Ben ShimolOndrej Samson Original Article 24 February 2021 Pages: 2771 - 2780
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer Rongpu LiangXudong ZhuBo Wei Original Article 26 February 2021 Pages: 2781 - 2793
Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy Yang HanBo SunYi Xuan Original Article 26 February 2021 Pages: 2795 - 2803
Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma Gennadi TulchinerRenate PichlerMartin Thurnher Original Article Open access 28 February 2021 Pages: 2805 - 2817
Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival Sen YangDongfang TangQingyi Wei Original Article 02 March 2021 Pages: 2819 - 2833
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment Xian-Ning WuDan SuNan Zhang Original Article 03 March 2021 Pages: 2835 - 2850
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy Jessica WentheSedigheh NaseriTanja Lövgren Original Article Open access 05 March 2021 Pages: 2851 - 2865
Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer Yamei ChenYing JinMing Chen Original Article 06 March 2021 Pages: 2867 - 2876
Correction to: Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited‑stage small cell lung cancer Yamei ChenYing JinMing Chen Correction 16 April 2021 Pages: 2877 - 2879
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody Yoshiro NakaharaTakaji MatsutaniTetsuro Sasada Original Article 09 March 2021 Pages: 2881 - 2892
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte Baojuan HanLina DongQingyuan Zhang Original Article Open access 10 March 2021 Pages: 2893 - 2909
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells Alejandra LeivasRuth M. RisueñoJoaquín Martínez-López Original Article Open access 10 March 2021 Pages: 2911 - 2924
Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients Chao WangTianYu HongXingang Cui Original Article 12 March 2021 Pages: 2925 - 2935
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer Shu-Fen ChiangKevin Chih-Yang HuangK. S. Clifford Chao Original Article 13 March 2021 Pages: 2937 - 2950
Tumor immune microenvironment in brain metastases from gynecologic malignancies Corey M. GillMegan R. D’AndreaValentin Kolev Original Article 13 March 2021 Pages: 2951 - 2960
The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL) Mehdi DehghaniNegin ShokrgozarNargess Arandi Original Article 15 March 2021 Pages: 2961 - 2969
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting Zhaozhen WuHaitao TaoYi Hu Original Article Open access 19 March 2021 Pages: 2971 - 2980
Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma Chien-Hsu ChenMu-Yao TsaiPo-Hui Chiang Original Article 19 March 2021 Pages: 2981 - 2990
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors Khanh T. DoClaire ManuszakMariano Severgnini Original Article 20 March 2021 Pages: 2991 - 3000
Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma Tetsushi MurakamiNobuyuki TanakaMototsugu Oya Original Article 14 July 2021 Pages: 3001 - 3013
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients Brigitte DrénoAmir KhammariNathalie Labarrière Clinical Trial Report Open access 12 June 2021 Pages: 3015 - 3030
Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma Rosanna L. WustrackEvans ShaoRoss A. Okimoto Research Report Open access 17 April 2021 Pages: 3031 - 3040
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports Alessandro InnoNicola MaureaStefania Gori Research Report 20 April 2021 Pages: 3041 - 3053
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo Anja Tatjana TeckSabrina UrbanSebastian Ochsenreither Correction Open access 25 June 2021 Pages: 3055 - 3055
Correction to: CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion Fei WangLi YangYi Zhang Correction 04 August 2021 Pages: 3057 - 3059
